DYNE THERAPEUTICS INC
NASDAQ: DYN (Dyne Therapeutics, Inc.)
最近更新时间: 2天之前, 11:20PM19.98
0.17 (0.86%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Dyne Therapeutics, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 5.0 |
| 内部交易活动 | -3.5 |
| 价格波动 | -1.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.80 |
|
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.56% |
| 机构持股比例 | 110.24% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Atlas Venture Life Science Advisors, Llc | 31 Dec 2025 | 9,130,465 |
| Fcpm Iii Services B.V. | 31 Dec 2025 | 5,462,846 |
| Tcg Crossover Management, Llc | 31 Dec 2025 | 4,615,144 |
| Siren, L.L.C. | 31 Dec 2025 | 3,502,941 |
| Perceptive Advisors Llc | 31 Dec 2025 | 3,478,944 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 50.00 (HC Wainwright & Co., 150.25%) | 购买 |
| 中 | 47.00 (135.24%) | |
| 低 | 38.00 (Chardan Capital, 90.19%) | 购买 |
| 平均值 | 45.00 (125.23%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 15.63 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Chardan Capital | 09 Mar 2026 | 38.00 (90.19%) | 购买 | 17.69 |
| 03 Mar 2026 | 38.00 (90.19%) | 购买 | 14.60 | |
| HC Wainwright & Co. | 03 Mar 2026 | 50.00 (150.25%) | 购买 | 14.60 |
| Morgan Stanley | 03 Mar 2026 | 47.00 (135.24%) | 购买 | 14.60 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| KERSTEN DIRK | - | 20.08 | -436,861 | -8,823,398 |
| 累积净数量 | -436,861 | |||
| 累积净值 ($) | -8,823,398 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 20.08 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| KERSTEN DIRK | 董事 | 20 Apr 2026 | 自动卖出 (-) | 125,274 | 20.02 | 2,507,985 |
| KERSTEN DIRK | 董事 | 17 Apr 2026 | 自动卖出 (-) | 211,974 | 20.41 | 4,326,389 |
| KERSTEN DIRK | 董事 | 16 Apr 2026 | 自动卖出 (-) | 17,773 | 19.91 | 353,860 |
| KERSTEN DIRK | 董事 | 15 Apr 2026 | 自动卖出 (-) | 81,840 | 19.98 | 1,635,163 |
| 日期 | 类型 | 细节 |
|---|---|---|
| 06 Mar 2026 | CNBC | FDA reversals leave investors worrying about the fates of other experimental drugs |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合